Yasuhara, Atsuhiro

Publications

Sort by

Co-Author Network

selected publications

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan. One health (Amsterdam, Netherlands). 2023 Academic Article GET IT
Times cited: 119
Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. The Journal of clinical investigation. 2023 Academic Article GET IT
Times cited: 2
Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. Vaccine. 2022 Academic Article GET IT
Times cited: 2
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nature communications. 2022 Academic Article GET IT
Times cited: 1
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022. Emerging infectious diseases. 2022 Academic Article GET IT
Times cited: 1
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nature microbiology. 2022 Academic Article GET IT
Times cited: 10
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022 Academic Article GET IT
Times cited: 101
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Internal medicine (Tokyo, Japan). 2022 Academic Article GET IT
Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization. Microbiology spectrum. 2022 Academic Article GET IT
Times cited: 20
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Research square. 2022 Article GET IT
Times cited: 96
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Nature communications. 2021 Academic Article GET IT
Times cited: 25
Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proceedings of the National Academy of Sciences of the United States of America. 2021 Academic Article GET IT
Times cited: 39
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Science advances. 2021 Academic Article GET IT
Times cited: 45
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021 Academic Article GET IT
Times cited: 84
Comparison of Rapid Antigen Tests for COVID-19. Viruses. 2020 Academic Article GET IT
Times cited: 118
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 548
Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan. Viruses. 2020 Academic Article GET IT
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nature microbiology. 2019 Academic Article GET IT
Times cited: 75
Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. 2019 GET IT
Times cited: 11
Soluble Recombinant Hemagglutinin Protein of H1N1pdm09 Influenza Virus Elicits Cross-Protection Against a Lethal H5N1 Challenge in Mice. Frontiers in microbiology. 2019 Academic Article GET IT
Times cited: 69
Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nature microbiology. 2019 Academic Article GET IT
Times cited: 30
Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2019 Academic Article GET IT
Times cited: 14
Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses. Frontiers in microbiology. 2018 Academic Article GET IT
Times cited: 16
Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2018 Academic Article GET IT
Times cited: 14
Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. The Journal of veterinary medical science. 2018 Academic Article GET IT
Times cited: 2
Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans. Emerging infectious diseases. 2018 Academic Article GET IT
Times cited: 28
Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Scientific reports. 2017 Academic Article GET IT
Times cited: 16
A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. Cell host & microbe. 2017 Academic Article GET IT
Times cited: 106
A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release. EBioMedicine. 2017 Academic Article GET IT
Times cited: 44
Risk assessment of recent Egyptian H5N1 influenza viruses. Scientific reports. 2016 Academic Article GET IT
Times cited: 15

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

A deep longitudinal analysis of next generation influenza vaccines in older adults. awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2022 - 2026
PanCoVac - Pan-coronavirus Vaccine Consortium awarded by American Society of Transplatation Key Personnel 2021 - 2024
CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 3) awarded by National Cancer Institute Key Personnel 2022 - 2023

more ...

less ...

Background

education and training

Ph.D., University of Tokyo (Japan) 2019
M.S., University of Tokyo (Japan) 2016
B.S., Yokohama National University (Japan) 2014

Contact

full name

Atsuhiro Yasuhara

primary email

aty4001@med.cornell.edu

VIVO Weill Cornell Medical College

Atsuhiro Yasuhara Postdoctoral Associate in Pediatrics

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email